{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:03:44Z","timestamp":1791180224737,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1136\/ard.2010.137422","type":"journal-article","created":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T21:12:00Z","timestamp":1292965920000},"page":"616-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":243,"title":["Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry"],"prefix":"10.1016","volume":"70","clinical-trial-number":[{"clinical-trial-number":"nct00224562","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"D","family":"Salmon-Ceron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Tubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Chosidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Bretagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Cuillerier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Michelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Pu\u00e9chal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Wendling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2010.137422_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/039463200902200301","article-title":"Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events.","volume":"22","author":"Murdaca","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1136\/ard.2010.137422_bib2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.137422_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.","volume":"39","author":"Mohan","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1136\/ard.2010.137422_bib4","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.137422_bib5","unstructured":"US Food and Drug administration. Manufacturers of TNF Blocker Drugs Must Highlight Risk of Fungal Infection, 2008. U.S. F.D.A., Silver Spring, Maryland. http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2008\/NEWS01879.html (accessed 30 December 2008)."},{"key":"10.1136\/ard.2010.137422_bib6","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1136\/ard.2010.137422_bib7","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.137422_bib8","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1136\/ard.2010.137422_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.24283","article-title":"Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients.","volume":"61","author":"Komano","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.137422_bib10","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/art.11151","article-title":"Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression.","volume":"48","author":"Netea","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.137422_bib11","first-page":"854","article-title":"Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience.","volume":"26","author":"Pe\u00f1a-Sagredo","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2010.137422_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.137422_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor alpha blockade therapy.","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1136\/ard.2010.137422_bib14","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1086\/508538","article-title":"Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists.","volume":"43","author":"Tubach","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"RR-4","key":"10.1136\/ard.2010.137422_bib15","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.","volume":"58","author":"Kaplan","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"10.1136\/ard.2010.137422_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/rheumatology\/kel236","article-title":"Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.","volume":"46","author":"Salliot","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2010.137422_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2036.2009.04037.x","article-title":"Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.","volume":"30","author":"Schneeweiss","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"5 Suppl 1","key":"10.1136\/ard.2010.137422_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.semarthrit.2005.01.009","article-title":"Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab.","volume":"34","author":"Wallis","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2010.137422_bib19","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.137422_bib20","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.137422_bib21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"10.1136\/ard.2010.137422_bib22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1128\/IAI.01011-07","article-title":"Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs.","volume":"76","author":"Chakravarty","year":"2008","journal-title":"Infect Immun"},{"key":"10.1136\/ard.2010.137422_bib23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks.","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1136\/ard.2010.137422_bib24","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.137422_bib25","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1136\/ard.60.12.1141","article-title":"Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus.","volume":"60","author":"No\u00ebl","year":"2001","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724146110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724146110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2010.137422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:25:07Z","timestamp":1736058307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724146110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0003496724146110"],"URL":"https:\/\/doi.org\/10.1136\/ard.2010.137422","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.8563957.9049056","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2010.137422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}